Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 Plus Anlotinib Combined With Oxaliplatin, Capecitabine in the First-line Treatment of Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
NCT04891900Phase 2Active, not recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in gastric cancer (GC), adenocarcinoma of the esophagogastric junction (AEG), sponsored by Henan Cancer Hospital. Started May 2021; status: active, not recruiting.
02
Drugs
benmelstobart
03
Conditions
gastric cancer (GC)adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT04891900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891900.